Certified by Founder
Lodge
Bicara Therapeutics
start up
United States
- Cambridge, Massachusetts
- 07/03/2023
- Series B
- $108,000,000
Bicara Therapeutics is a clinical-stage company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. The company's dual-action biologics are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy. For more, please visit: bicara.com.
- Industry Biotechnology Research
- Website https://www.bicara.com/
- LinkedIn https://www.linkedin.com/company/bicara-therapeutics/
Iceotope | $26,000,000 | (May 15, 2026)
Harken Sweets | Undisclosed Amount | (May 15, 2026)
Graphon AI | $8,300,000 | (May 15, 2026)
Ranger AI | $8,400,000 | (May 15, 2026)
Wirestock | $23,000,000 | (May 15, 2026)
GridCARE | $64,000,000 | (May 15, 2026)
Chromie Health | $2,000,000 | (May 15, 2026)
Novella | $21,000,000 | (May 15, 2026)
Flick | $6,000,000 | (May 15, 2026)
Synthetic | $10,000,000 | (May 14, 2026)
SwishX | $2,200,000 | (May 14, 2026)
Urologic Health | $11,000,000 | (May 14, 2026)